Among the commemorative stamps of scientific and technological innovation II issued by China Post on November 1, the fourth is the new drug gv-971 for Alzheimers disease treatment. Photo source: released in Shanghai
The news that Chinas original new drugs for Alzheimers disease have been approved for market surprised clinicians.
Alzheimers disease, a degenerative disease of the central nervous system, is the most common type of Alzheimers disease.
Data statistics show that at present, there are at least 50 million Alzheimers patients in the world, with an explosive growth, which is expected to reach 150 million by 2050. In China, the number of Alzheimers patients has exceeded 10 million, ranking first in the world, and the number of new cases increases by more than 300000 every year.
Dr. Deng Yulei, neurology department of Ruijin Hospital Affiliated to Shanghai Jiaotong University Medical College, said in an interview with surging journalists that Alzheimers disease has attracted great social attention now, and peoples attention to the disease is also increasing year by year. Ruijin Hospital opened a special outpatient service for memory disorders as early as the 1990s. At that time, we came to see that Many patients cant take care of themselves or even dont know their families, but now many patients in the early stage of the disease find that memory is lower than before, they will come to see a doctor immediately.
Deng said that with the development of aging, the age of patients with Alzheimers disease has also expanded from 50-60 years old to 60-90 years old, especially those over 80 years old, and the incidence is increasing year by year.
From the symptoms of this disease, memory decline is the most common clinical manifestation, in addition to the decline of language function and spatial recognition function, which is easy to lead to patients lost or lost, and some of them are poor logic ability, even personality changes, which are easy to be ignored, in fact, this is part of the symptoms of Alzheimers disease. Deng said.
Because the pathogenesis of Alzheimers disease is not clear, there have been clinical treatment difficulties for many years. There are two main types of existing clinical treatment drugs, one is cholinesterase inhibitors, such as donepezil, carbalastine tartrate, the other is NMDA receptor coordinator, such as memantine hydrochloride, but these three drugs still can not block or reverse the disease, can only play a remission There has been no new progress in the research and development of new drugs for Alzheimers disease for 17 years. Drugs like memantine have been on the market in the late 1990s abroad.
Why is it difficult to develop new drugs? Deng Yulei pointed out that this is mainly because the pathogenesis of Alzheimers disease is still unclear. Only by finding the pathogenesis can we block the progress of the disease and significantly improve the symptoms. At present, the etiology includes heredity, trauma, history of encephalitis and so on. It may also be related to spirit and emotion. The etiology is very complex. It can be seen that its treatment also needs multi angle and multi-target clinical research.
The emergence of ganlute sodium capsule (gv-971) has given clinical experts hope. This drug has carried out multi center clinical research in China and recruited 818 patients from 34 sites in China to participate in phase III clinical trials.
The Ruijin hospital team also participated in the clinical study, Deng said: this study mainly adopts double-blind, placebo-controlled study, as a new drug, after half a year of clinical verification, it can significantly improve the cognitive dysfunction of patients. We just learned that nine phase one was approved by the State Food and Drug Administration on November 2, 2019, and can be applied to patients with mild to moderate Alzheimers disease. As a clinician, we look forward to adding a powerful weapon in the fight against Alzheimers disease.